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Abstract
Introduction: Ulcerative colitis (UC) is an idiopathic inflammatory bowel disorder, which requires lifelong treatment. It gener-
ates substantial direct and indirect costs, and significantly affects the quality of life, especially in the active state of the disease.
Aim: To evaluate the direct and indirect costs of UC as well as to assess disease activity and quality of life reported by pa-
tients with UC in Polish settings. 
Material and methods: A questionnaire, cross-sectional study among UC patients as well as physicians involved in the ther-
apy of the patients was conducted. The Clinical Activity Index (CAI) was used to assess disease activity, and the WPAI question-
naire to assess productivity loss. The quality of life was presented as utility calculated using the EQ-5D-3L questionnaire. Indirect 
costs included absenteeism, presenteeism, and informal care were assessed with the Human Capital Approach and expressed 
in euros (€). The productivity loss among informal caregivers was valuated with the average wage in Poland. Correlations were 
presented using the Spearman’s coefficient, and the between-group difference was assessed with Mann-Whitney U-test. 
Results: One hundred and forty-seven patients participated in the study, including 95 working persons. Mean cost of absen-
teeism and presenteeism was €1615.2 (95% CI: 669.5–2561.0) and €3684.4 (95% CI: 2367.8–5001.1), respectively, per year per 
patient with a disease in remission. The mean yearly cost of productivity loss due to informal care was estimated to be €256.6 
(range: 0.0–532.6). The corresponding values for patients with active disease were: €8,913.3 (95% CI: 6223.3–11,603.3), €4325.1 
(95% CI: 2282.4–6367.8), and €2396.1 (95% CI: 402.0–4390.3). The between-group difference in total indirect costs, cost of 
absenteeism, and cost of informal care was statistically significant (p < 0.05). The average weighted monthly costs of therapy 
with particular drugs categories (e.g. mesalazine or biologic drugs) differed significantly between active disease or remission 
patients. The difference in utility values between patients with a disease in remission (0.898 ±0.126) and patients with an active 
disease (0.646 ±0.302) was statistically significant. 
Conclusions: Our study revealed the social burden of UC and high dependency of direct and indirect costs as well as quality 
of life on the severity of UC in Poland. The statistically significant differences were identified in total direct and indirect cost, 
cost of absenteeism, cost of informal care, and health-related quality of life among patients with an active disease compared 
to patients with a disease in remission.
Introduction
Ulcerative colitis (UC) is an idiopathic inflammatory 
bowel disorder characterised by an inflammatory re-
action involving the colonic mucosa [1, 2]. The clinical 
course is unpredictable and marked by alternating pe-
riods of exacerbations and remissions, which may oc-
cur spontaneously or in response to treatment changes 
or intercurrent illnesses [3, 4]. The prevalence of UC 
in Europe ranges from 4.9 to 505 per 100,000 people, 
while in North America it ranges from 37.5 to 248.6 
per 100,000 people [5]. People affected with UC require 
expensive, lifelong treatment, which generates great di-
rect costs to the public payer. Additionally, it has a sig-
nificant impact on the quality of life, especially in the 
active state of the disease. Ulcerative colitis is assumed 
to impose a considerable medical and societal burden, 
especially when the disease is active. 
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Indirect costs or productivity losses are the labour 
earnings that are forgone as a result of an adverse 
health outcome, i.e. illness, death, side effects, or time 
spent on treatment. Indirect costs consist of two major 
components: absenteeism and presenteeism. Absentee-
ism refers to the number of days on sick leave, periods 
of unemployment caused by a disease, and early leav-
ing of the labour market due to sickness. Presenteeism 
refers to a situation when a sick person is present at 
work but his or her own productivity is lower than av-
erage due to the disease [6]. There are two main meth-
ods to calculate the indirect costs: the Human Capital 
Approach, and the Friction Cost Approach. The Human 
Capital Approach (HCA) converts the value of work that 
will not be done in the future due to disease into the 
real costs from a social perspective. The HCA can also 
take into account the loss of productivity associated 
with early retirement or early death of the patient. The 
HCA is based on the assumption that work not done 
due to disease is a decrease of human capital and is 
a burden to society. The Friction Cost Approach (FCA) 
considers productivity losses until a new person is em-
ployed as a substitute for the sick one. The FCA is based 
on the assumption that society can replace a sick per-
son in order to prevent productivity losses. This method 
requires access to detailed economic data and is more 
sophisticated than HCA, which is probably the reason 
why the vast majority of studies use the HCA during 
calculation of indirect costs [6]. Indirect costs calculated 
with FCA methodology are generally much lower than 
those obtained with HCA.  
Aim
We conducted a cross-sectional study to assess the 
relationship between the disease activity assessed by 
physicians and corresponding direct and indirect costs 
as well as quality of life of patients with UC.
Material and methods 
Study design
A questionnaire-based, self-report survey was used 
to collect data on direct costs, health-related quality 
of life, and productivity loss of UC patients in Poland. 
Alongside this, disease activity was assessed with a sur-
vey carried out among physicians, and the general char-
acteristics of patients with UC were collected. 
The study was performed in a group of 147 patients 
with a diagnosis of UC as well as among their physi-
cians in the period from mid-August to September 2016 
(cut-off date: 30 September 2016); volunteers aged 
18 years or older, with a diagnosis of UC, from random-
ly selected inpatient and outpatient medical centres in 
Poland, were enrolled in the study. No exclusion crite-
ria that would preclude participation were used among 
patients who met the inclusion criteria. Centres from 
different regions of Poland were included to get a sam-
ple of patients with the greatest representativeness 
for the Polish population. The whole country was di-
vided into five regions, and in each of these regions 
the random selection of medical centres engaged in UC 
therapy was performed to obtain a heterogeneous pop-
ulation of UC patients. All calculations were carried out 
for the general population of patients with UC and also 
for subgroups of patients with active disease and with 
disease in remission. The differences of obtained values 
in those two groups were also assessed. 
Questionnaire
The questionnaire consisted of two parts. Part “A” 
was designed to be completed by the physicians and in-
cluded questions that enable an assessment of disease 
activity but also a current pharmacological treatment. 
Part “B” was designed to be completed by UC patients 
and included questions concerning the general charac-
teristics of patients (age, sex, place of living, date of 
disease onset, education, comorbidities), quality of life, 
direct costs, influence of the disease on usual activities, 
and paid and unpaid work. Both parts were designated 
with a matching blank patient’s acronym/number as-
signed by physicians. 
We used a clinical activity index (CAI), also known 
as the Rachmilewitz index, to assess the disease ac-
tivity. Within this scale physicians who take care of UC 
patients assess the disease activity taking into account 
the following parameters: number of stools, blood in 
stools, global assessment, abdominal pain or cramps, 
body temperature, extraintestinal manifestations, 
and results of laboratory test. The CAI score ranges 
from 0 to 29 (higher score means more severe disease). 
Within this scale it is possible to categorise two types 
of patients: those with inactive disease/remission 
(CAI score < 5) and those with active disease (CAI score 
≥ 5) [7].
Health-related quality of life of the patients was as-
sessed with the EuroQol questionnaire five-dimension, 
three-level version (EQ-5D-3L) [8]. In order to calculate 
the utility weights, the responses to the EQ-5D-3L were 
evaluated with the Polish tariffs [9]. 
To assess the productivity loss the Work Productiv-
ity and Activity Impairment (WPAI) questionnaire was 
used, which is a standard analytic tool commonly used 
to assess absenteeism and presenteeism due to a dis-
ease [10]. After consultation with experts, additional 
questions were added to include also the part-time em-
ployees, patients on rehabilitation benefit, or other pro-
fessionally inactive patients (on illness benefit, unable 
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to work, still studying, inactive due to other reasons). 
Questions concerning informal care were also included 
in the questionnaire. 
Resource evaluation
The Human Capital Approach was used to estimate 
indirect costs due to absenteeism and presenteeism. 
A macroeconomic indicator for Poland was considered 
– gross domestic product (GDP) per working hour of 
a person with a professional activity in Poland in the 
year 2015 [11]. The correction factor of 0.65 was used, 
which is the conventional mean value of output elas-
ticity of labour according to the Cobb-Douglas function 
of production [12]. The final unit cost of productivity 
loss at paid work per hour was estimated to be €8.15 
(the exchange rate valid for 2016 was €1 = 4.36 PLN). 
The informal care included the time inputs of relatives 
without payment. The unit cost was estimated to be 
€5.90, which was an average income per hour of work 
in the third quarter of 2016 in Poland [11]. 
Statistical analysis 
Continuous variables were summarised using means 
or medians and standard deviations (SDs) or 95% confi-
dence intervals (CIs) or ranges, while nominal variables 
were summarised using frequencies. Mann-Whitney 
U test for continuous variables was used to compare 
the subgroups – patients with active disease and pa-
tients with disease in remission.
Based on dosage of particular drugs indicated by 
patients, the monthly therapy costs from public payer's 
perspective (reimbursement) and the patient’s perspec-
tive (co-payment) were calculated for each patient. 
The relationship between the disease activity, mea-
sured with CAI scale, and both the indirect costs and 
utility weights was assessed with Spearman’s rank cor-
relation coefficient. 
Additionally, data on total indirect costs were pre-
sented on box-whisker plots, where a point presents 
a median value, a box presents the first and third quar-
tiles, and whiskers present minimum and maximum 
values. The relationship between cost of absenteeism, 
total indirect cost, utility weights, and disease activity 
(CAI score) was presented on scatterplots. Statistical 
analyses were performed using Statistica®.
Results 
General characteristics 
We obtained 147 completed questionnaires from 
patients fulfilling the inclusion criteria, aged from 18 
to 79 years (average age: 39.0 ±13.4 years; median val-
ue: 36.0 years); the total response rate was estimated 
at 82%. The general characteristics of all patients are 
presented in Table I.
The majority of patients completed the questionnaire 
during the ambulatory visit (69.2%), while the others 
completed the questionnaire during the hospitalisation, 
which was longer than 1 day (24.7%) or equalled 1 day 
(6.2%). Physicians assessed the extent of involvement in 
accordance with Montreal classification as: left-sided UC 
in 43.5% of patients, extensive UC in 30.3%, and ulcer-
ative proctitis in 26.2%. The average value of CAI was 4.9 
(95% CI: 3.9–5.8, median value: 3.0). The severity of the 
disease was also assessed by physicians. Disease in clin-
ical remission was seen in 27.4% of patients, 36.8% had 
mild disease, 21.1% had moderate disease, and 14.7% of 
patients had severe disease. 
The average age at diagnosis was 31.7 ±12.8 years 
(median value: 29.0 years). The general wellbeing was 
moderate and equalled 6.3 (95% CI: 5.9–6.7, median 
Table I. General characteristics of all and working patients with UC included in the study
Characteristic All patients Working patients
Age [years] 39.03 ±13.42, range: 18–79 38.83 ±10.27, range: 22–68
Male 69 (46.94%) 44 (46.32%)
Disease onset [years] 31.65 ±12.76, range: 3–70 31.66 ±10.72, range: 3–63
Place of living City ≥ 100,000 citizens 95 (66.43%) 66 (72.53%)
City < 100,000 citizens 39 (27.27%) 22 (24.18%)
Village 9 (6.29%) 3 (3.30%)
Education Higher 55 (38.19%) 43 (46.24%)
Secondary 80 (55.56%) 49 (52.69%)
Basic 9 (6.25%) 1 (1.08%)
Comorbidities 37 (25.17%) 23 (24.21%)
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value: 6.0), while the minimum and maximum possible 
values were: 1 (the worst) and 10 (the best), respec-
tively. The influence of the disease on daily activities 
was rather limited and equalled 3.8 (95% CI: 3.2–4.3, 
median value: 3.0), while the minimum and maximum 
possible values were: 1 (no influence) and 10 (the high-
est influence), respectively. 
Data on employment status was collected for all 147 
patients, of which 95 (64.6%) were currently working. 
The general characteristics of working patients were 
presented in Table I. Among all 95 working patients, 
89 had paid job, one was retired, and one was receiv-
ing rehabilitation benefit. One patient was still studying 
and also working, but the form of employment was not 
mentioned. Three patients did not determine the form 
of employment. 
For all working patients, data on disease activity 
with the CAI questionnaire were available. The average 
value of CAI was 5.1 (95% CI: 3.9–6.3; median value: 
3.0). Among 95 working patients with UC, 64.2% had 
remission according to CAI score.
Direct costs
Patients reported on average 1.6 ±1.3 (range: 
0.0–8.0, median value: 1.0) medical consultations per 
month, from which on average 0.8 were private (range: 
0.0–4.0, 95% CI: 0.7–1.0; median value: 1.0). The cost 
of one private consultation was on average €30.6 ±6.7 
(range: 18.3–45.9, median value: 29.8).
Patients reported on average 0.6 hospitalisations 
per month (range: 0.0–6.0, 95% CI: 0.4–0.8) and the 
median length of stay was 3.0 days (range: 0.0–21.0, 
average value: 6.1, 95% CI: 4.3–7.8). Hospitalisations 
are fully reimbursed from public funds (by National 
Health Fund) in Poland, and its cost ranged from about 
€572 to €954.
The majority (48.0%) of patients spent from €23 to 
€46 monthly on drugs used in the treatment of UC, and 
only 1.4% spent €92 – €138. The additional expenditures 
such as informational materials, dietary supplements are 
lower – 42.5% of patients spent from €0 to €23 monthly.
Almost 90% of patients took mesalazine, while bio-
logical treatment of UC (adalimumab or infliximab) was 
used in almost 13% of patients (Figure 1). The aver-
age weighted monthly costs of therapy with particular 
drugs per patient differed significantly in between both 
considered groups: patients with active disease and pa-
tients with disease in remission (Table II). 
Absenteeism and presenteeism
All working patients
The average annual number of days off work 
due to the illness among working patients was 66.3 
(95% CI: 45.8–86.8, range: 0–258). The average re-
duction of work productivity due to absenteeism was 
25.7% (95% CI: 17.8–33.7%, range: 0–100%). Mean cost 
of absenteeism was €4161.1 (95% CI: 2839.1–5483.0) 
per year per working patient.
Average productivity loss at paid work of a working 
patient was 37.0% (95% CI: 29.6–44.4; range: 0–100%), 
which represents the extent of presenteeism. Mean cost 
of presenteeism was €3907.9 (95% CI: 2815.8–5000.0) 
per year per patient with any occupational activity. 
Total average reduction of productivity due to UC 
(reduction resulted from both absenteeism and pre-
senteeism) was 45.1% (95% CI: 36.9–53.3%, range: 
0–100%). Total average indirect cost per year per work-
ing patient was €8069.0 (95% CI: 6532.9–9605.1).
The cost of absenteeism and total indirect cost was 
moderately-to-strongly correlated with CAI score. The 
Spearman’s coefficients were 0.6475 and 0.5459, respec-
tively (Figures 2, 3). No statistically significant correlation 
was found for cost of presenteeism and CAI score. 
Patients with a disease in remission
The average annual number of days off work due 
to illness among working patients with a disease in re-
mission was 27.4 (95% CI: 10.8–44.0, range: 0–258). 
The average productivity loss due to absenteeism was 
11.1% (95% CI: 4.4–17.9%, range: 0–100%). Mean cost 
of absenteeism was €1615.2 (95% CI: 669.5–2561.0) 
per year per patient with any occupational activity. 
Average productivity loss of paid work for a working 
patient with a disease in remission was 24.3% (95% CI: 
16.1–32.4%, range: 0–100%). Mean cost of presentee-
ism was €3684.4 (95% CI: 2367.8–5001.1) per year per 
patient with any occupational activity. 
Total average reduction due to UC (reduction re-
sulted from both absenteeism and presenteeism) was 
Figure 1. Pharmacological treatment of UC
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Table II. Monthly pharmacotherapy costs per patient
Drugs Perspective of public 
payer (reimbursement) 
and patient (co-payment) 
Monthly costs [€] P-value
Active disease Remission 
Biologics Public payer 236.38 52.40 0.0005
Patient 0.00 0.00 –
Prednisone Public payer 4.29 1.02 < 0.0005
Patient 1.04 0.25 < 0.0005
Hydrocortisone Public payer 10.63 0.78 < 0.0005
Patient 4.56 0.33 < 0.0005
Sulfasalazine Public payer 1.19 1.76 0.5621
Patient 0.13 0.20 0.5621
Mesalazine Public payer 28.90 23.91 0.0247
Patient 15.70 12.99 0.0247
Azathioprine Public payer 4.11 2.80 0.0616
Patient 0.70 0.43 0.0235
Mercaptopurine Public payer 0.40 0.00 0.0501
Patient 0.05 0.00 0.0501
Budesonide Public payer 1.94 8.98 0.0981
Patient 0.01 0.07 0.0981
Ciprofloxacin Public payer 1.21 0.08 < 0.0005
Patient 2.68 0.19 < 0.0005
Metronidazole Public payer 0.00 0.00 –
Patient 13.25 2.49 < 0.0005
Figure 3. The relationship between total indirect 
cost and CAI score
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Figure 2. The relationship between cost of ab-
senteeism and CAI score
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30.2% (95% CI: 21.2–39.3%, range: 0–100%). Total av-
erage indirect cost per year per working patient was 
€5299.7 (95% CI: 3719.6–6879.8).
Patients with an active disease 
The average annual number of days off work due 
to the illness among working patients with an active 
disease was 138.8 (95% CI: 99.4–178.3, range: 0–258). 
The average productivity loss due to absenteeism was 
52.9% (95% CI: 37.7–68.1%, range: 0–100%). Mean cost 
of absenteeism was €8913.3 (95% CI: 6223.3–11,603.3) 
per year per patient with any occupational activity. 
Average productivity loss at paid work of working 
patient with active disease was 60.6% (95% CI: 49.5–
71.7%, range: 0–100%). Mean cost of presenteeism was 
€4325.1 (95% CI: 2282.4–6367.8) per year per patient 
with any occupational activity. 
Total average reduction due to UC (reduction re-
sulted from both absenteeism and presenteeism) was 
72.6% (95% CI: 61.0–84.3%, range: 0–100%). Total av-
erage indirect cost per year per working patient was 
€13,238.4 (95% CI: 10,819.2–15,657.5).
Mann-Whitney U test indicated the significant differ-
ence (p < 0.05) in average value of cost of absenteeism 
and total indirect costs between the two analysed groups: 
active disease and disease in remission. Median value, as 
well as range and 1st and 3rd quartiles of total indirect cost 
are presented in box-whiskers plot (Figure 4).
Informal care 
Twenty working patients (21.3%) declared that they 
require assistance in performing usual activities, which 
is supported by their relatives. Patients received the as-
sistance in performing usual activities for an average 
of 16.6 (95% CI: 6.0–27.2, median value was 9.0) hours 
per week. The mean cost of productivity loss due to 
informal care was estimated to be €1000.8 (95% CI: 
277.1–1724.5) per year.
Similar analyses were performed for two subgroups: 
working patients with active disease and working pa-
tients with disease in remission.
In the first group 39.4% patients declared that they 
require assistance in performing usual activities, while 
among working patients with a disease in remission 
only 11.5% declared the need of such support. Patients 
with an active disease and with a disease in remission 
received assistance in performing usual activities for an 
average of 20.8 (95% CI: 5.0–36.5, median value: 12.0) 
and 8.3 (range: 4.0–25.0, median value: 5.0) h/week, 
respectively. The mean yearly cost of productivity loss 
due to informal care was estimated to be €2396.1 
(95% CI: 402.0–4390.3) among working patients with 
active disease and €256.6 (range: 0.0–532.6) among 
working patients with disease in remission. 
Mann-Whitney U test indicated the significant dif-
ference (p < 0.05) in the average cost of informal care 
between two analysed groups: patients with active dis-
ease and with disease in remission. 
Health-related quality of life
Data on the quality of life were reported by 144 
(97.1%) respondents. The average utility index in all 
patients was estimated to be 0.811 ±0.237, and 0.809 
±0.234 for working patients. Patients with active dis-
ease had significantly lower utility indexes (0.646 
±0.302) compared to patients with a disease in re-
mission (0.898 ±0.126). The corresponding values for 
working patients with active disease and with disease 
in remission were 0.665 ±0.259 and 0.889 ±0.174, re-
spectively. The difference in utility values between the 
above groups was statistically significant based on 
Mann-Whitney U test (p < 0.05).
Utility indexes among study participants were cor-
related with CAI score (Spearman’s coefficient of –0.702 
for all patients, Figure 5, and –0.655 for working pa-
tients, p < 0.05).
The relationship between the utility indexes and the 
indirect costs was assessed in working patients. The 
correlation between the above parameters was nega-
tive and moderate and equalled –0.445, which means 
that higher indirect costs were observed among pa-
tients with lower utility weights.
Discussion
Within this study we assessed the disease activity 
with CAI questionnaire as well as costs and quality of 
life of patients with UC in Poland. The study was carried 
Figure 4. Total indirect costs according to dis-
ease activity: 1 – patients with active disease, 
0 – patients with disease in remission
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out among diagnosed adult patients with UC and their 
physicians, who assessed the diseases activity and se-
verity, and current medical treatment. Additionally, we 
assessed the relationship between the disease activity 
and indirect costs as well as utility weights. It was prov-
en that the activity of the disease significantly affected 
total indirect costs and indirect costs due to absentee-
ism. Presenteeism – the productivity of sick person at 
work – was not dependent from disease activity. The 
reason for this was probably the fact that patient who 
felt bad, stayed at home and took a day (days) off work 
due to the illness, which influenced absenteeism and 
did not affect presenteeism. Conducted analysis in-
cluded also cost of informal care, which was calculated 
based on the need of assistance in performing usual ac-
tivities and the number of hours per week of such help. 
The above cost was also dependent from the disease 
activity, i.e. it was significantly higher for patients with 
active disease compared with patients with disease in 
remission. We calculated also direct costs, mainly re-
sulting from pharmacotherapy. All drugs that were in-
dicated by the physicians were included in the analysis, 
and the treatment costs with each drug for each patient 
were calculated. Finally, it was shown that the pharma-
cotherapy costs of almost all drugs differed significantly 
comparing patients with active or remission stage of 
disease. This resulted from the fact that patients in re-
mission much less frequently need pharmacotherapy.
There have been no previous studies that have as-
sessed the disease activity measured with CAI ques-
tionnaire, direct and indirect costs, and quality of life of 
Polish patients with UC. Therefore, it seemed necessary 
to conduct such a study. Indirect costs included both ab-
senteeism and presenteeism, and also the cost of infor-
mal care, which is very rarely assessed in cost studies. 
The main calculations were made for all patients and 
also for subgroups: patients with active disease and 
with disease in remission. 
In the calculations of indirect costs only working 
patients with diagnosed UC were included, who consti-
tuted about 65% of all study participants. 
The main advantage of this study was the size of the 
study population and its diversification. The study was 
carried out in randomly selected, Polish medical cen-
tres from the following cities: Poznan, Wroclaw, Opole, 
Katowice, Lodz, and Warsaw (two medical centres). The 
randomisation was performed to obtain a sample of 
patients that best represented the Polish population. 
The whole country was divided into five regions, and in 
each of those regions the random selection of medical 
centres engaged in UC therapy was performed. Disease 
activity was assessed with a reliable questionnaire – CAI 
– by physicians, which is an additional strength of this 
Figure 5. The relationship between utility weights 
and CAI score
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study because patient-based assessment of disease 
activity may be less precise. Answers were collected 
during clinical examination, which assured the highest 
reliability – the biases resulting from self-reporting were 
eliminated. Direct costs were assessed by the patients 
and did not include all possible categories, which can 
constitute a limitation. 
Evidence on indirect costs of UC is available but typ-
ically provides information on the loss of productivity 
due to absence from work and due to lower productivity 
at work, and our study was the first one providing ad-
ditional information on indirect costs as well as on the 
costs of informal care in Polish settings. There is lack of 
such information also for countries from the CEE region, 
which made our research quite interesting. 
In order to compare our results with findings of 
other investigators, we performed a review of medical 
databases. We discovered some studies considering the 
association between the disease activity and quality of 
life or indirect costs across Europe, but such studies in 
Polish settings were not identified. 
The study by Casellas et al. [13], which included 
UC patients, showed that Spearman’s correlation co-
efficients between health-related quality of life mea-
sured with Inflammatory Bowel Disease Questionnaire 
(IBDQ) and clinical and colonoscopic indices were 
statistically significant (p < 0.01) and equalled from 
–0.67 to –0.61 and from –0.70 to –0.67, respectively, 
depending on the questionnaire – full form IBDQ-36 or 
short form IBDQ-9. The results obtained in our analysis 
showed a slightly lower correlation of –0.55, but the 
quality of life was measured in a different way – using 
an EQ-5D questionnaire, as well as disease activity, 
which was measured with P-CAI questionnaire. Gibson 
et al. [14] calculated the mean (standard deviation – 
SD) EQ-5D-5L scores among UC patients, which were 
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greater for patients in remission (0.81 (0.18)) than for 
patients with active disease (0.72 (0.19), p < 0.001). 
The same dependence was observed in our analysis. 
Patients in remission and with mild disease had much 
less impairment than patients with moderate/severe 
disease for every type of work and activity impair-
ment (i.e. work time missed, overall work impairment, 
impairment while working, activity impairment). In 
a study by Mandel et al. [15], among employed IBD (UC 
and CD) patients, absenteeism and presenteeism was 
reported in 25.9% and 60.3% of patients, respectively, 
leading to a 28% loss of work productivity and a 32% 
activity loss. It was significantly different according to 
IBD activity assessed with partial Mayo score in the 
case of UC. The significant difference in productivity 
loss between patients with active disease and patients 
with disease in remission was also observed in our 
analysis. Among 226 UC patients, moderate correla-
tion was also observed by Taleban et al. [16] between 
the Mayo endoscopic score and health-related quality 
of life measured with the Short Inflammatory Bowel 
Disease Questionnaire (SIBDQ; r = –0.56), and disease 
activity measured with Simple Clinical Colitis Activity 
Index (SCCAI; r = 0.55).
Our study was the first one to assess the relation-
ship between the disease activity measured with CAI 
with quality of life measured with EQ-5D and indirect 
costs, but similar assessments were made taking into 
account different measures of health-related quality of 
life and activity of the disease. All of the identified stud-
ies confirm the results of our analysis. Health-related 
quality of life and productivity loss are significantly dif-
ferent among patients with active disease and patients 
with disease in remission. No studies were identified 
that included informal care and the influence of the dis-
ease on the daily activities, other than paid work.
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